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Genomic variationAdvances in DNA sequencing technologies have made it possible to rapidly, accurately and affordably
sequence entire individual human genomes. As impressive as this ability seems, however, it will not likely
amount to much if one cannot extract meaningful information from individual sequence data. Annotating
variations within individual genomes and providing information about their biological or phenotypic impact
will thus be crucially important in moving individual sequencing projects forward, especially in the context of
the clinical use of sequence information. In this paper we consider the various ways in which one might
annotate individual sequence variations and point out limitations in the available methods for doing so. It is
arguable that, in the foreseeable future, DNA sequencing of individual genomes will become routine for
clinical, research, forensic, and personal purposes. We therefore also consider directions and areas for further
research in annotating genomic variants.genome sequencing edited by Jian-Bing Fan.
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1.1. The DNA sequencing era
The introduction and nowwide-spread availability of efﬁcient and
cost-effective high-throughput DNA sequencing technologies have
radically changed theway inwhich geneticists can approach the study
of human diseases. For example, traditional strategies for identifying
or ‘mapping’ genes and/or genetic variants that inﬂuence a disease
typically involved tracing co-segregation or linkage disequilibrium
(LD) patterns between a particular genetic variant and a phenotype
either among family members, as in classical linkage analysis [1,2], or
across unrelated individuals, as in more contemporary LD mapping-
based association analysis [1,3]. The goal of these strategies is to
identify a unique ancestral chromosomal segment or haplotype that is
‘marked’ by speciﬁc variants that track along with a disease from
generation-to-generation or between individuals with the phenotype.
The basic intuition is that this segment or haplotype contains a variant
that causally inﬂuences the phenotype and the neighboring material
is simply being inherited along with this causal variant. Thus, the
identiﬁed associations between genetic variants and a particular
phenotype resulting from these strategies are often indirect and
merely pointed researchers to a genomic region that might harbor
variants that are causally-related to the phenotype in question. The
subsequent identiﬁcation of the causal variants in the region
implicated in a linkage or LD-mapping study is not always trivial
and can require a great deal of effort.
Whole genome sequencing can facilitate tracing segregation and/or
LD patterns involving a phenotype of interest or a haplotype that
harbors a variant that inﬂuences thatphenotype. This is the casebecause
one does not have to ﬁrst identify a region harboring a variant and then
seek to determine the trait-inﬂuencing variant on the haplotype at a
later time, but rather would have all the information needed for
identifying an association and a causal variant simultaneously. DNA
sequencing a genomic region or entire genomes among individuals, e.g.,
with and without a particular phenotype, will reveal all the genetic
variants the individuals possess, shifting the problem from merely
identifying a region harboring a variant to determining which among
the many variants observed in the region (or genome as a whole) are
likely to inﬂuence the phenotype [4]. As with traditional gene mapping
methods, the use of DNA sequencing technologies to identify variants
associated with a particular phenotype requires sophisticated data
analysis methodologies [5]. The search for variants likely to be
associated with a phenotype from sequence data can be greatly
enhanced by leveraging knowledge about the variants discovered,
such as their positions and likely functional effects, since this knowledge
can be used to prioritize variants or weight them in relevant statistical
analyses [5]. Assigning biological meaning to sequence variants, i.e.,
‘annotating’ them, is the subject of this review, as there are a variety of
ways variants can be annotated and exploited in various contexts.
There are other reasons why sequence annotations are important
in modern human genetics. For example, many clinical diagnoses of
congenital conditions require an understanding of variants an indi-
vidualmight possess that could be pathogenic, and this understanding
requires the use of methods for classifying and annotating existing
and novel variants, as is the case with BRCA1-associated breast cancer
and similar conditions [6]. In addition, many contemporary sequenc-
ing initiatives focus on the mere identiﬁcation and cataloging of
naturally-occurring sequence variants, such as the International
HapMap Project [7], the 1000 Genomes Project [8], and the Cancer
Genome Atlas Project [9], leaving it open to others to determine the
biological signiﬁcance of the variants identiﬁed. Finally, as whole
genome sequencing (WGS) of individual human genomes becomes
more efﬁcient, the need for putting the variation across individual
genomes into a biological context will become more pronounced
[10–12].1.2. Annotating sequence variations
There are many ways in which one can assign a label or biological
meaning to a position in the human genome that varies among
individuals in the population at large. The simplest is to identify a
variant's position either within the sequence as a whole or in a
putative functional genomic element. This is not trivial, as the
genomic positions must be based on landmark sites in the genome
or with respect to a ‘reference’ genome, such as that used for the
human genome browser [13,14] or the HuRef genome [15]. The use of
reference genomes can be problematic, however, since human
genomes vary in size due to repetitive elements and functional
elements are continually being identiﬁed and updated. In addition,
sequence variants, perhaps despite being in a functional element, do
not often perturb the actual functioning of a position or functional
element [16]. The evolutionary or population history of a variant
might shed light on a variant's effect, but how one determines and
assigns the functional impact of variant given the biological realities of
e.g., redundancies and feedback in disease pathways, general
buffering effects, and tissue-speciﬁc gene effects, is not trivial [16–
18], nor is understanding the origins of a variant [19].
One important issue surrounding the annotation of sequence
variations involves the nature of the variants themselves [20]. Single
nucleotide variants (SNVs) are the most abundant forms of variation
and have been given a great deal of attention. Small insertions and
deletions (‘indels’), repetitive sequence, copy number variations
(CNVs), and inversions have been given less attention, although they
are beginning to receive more. Another issue relating to variant
annotation involves the potential context-speciﬁcity of particular
effects. Epistasis, gene×environment interactions, or generalmultilocus
and genetic background effects may mitigate or enhance the effect of
any single variant. In addition, phase information (i.e., knowledge of the
nucleotide content of the two homologous chromosomes an individual
inherits in the vicinity of a variant) is known to inﬂuence the functional
effects of a variant in many cases [21].
In the remainder of this review we consider the various methods and
strategies for annotating DNA sequence variation. These strategies range
from merely identifying the genomic elements (e.g., genes, promoters,
microRNA binding sites, etc.) a variant resides in, predicting the likely
functional effect of an association using sophisticated statistical algo-
rithms, and directly examining the impact of the variant on phenotypic
expression using contrived experimental settings involving in vitro or
model organism-based assays. By ‘functional’ it is meant that a variant
results in a change of phenotype either at the basic molecular level (e.g.,
change in binding strength of a transcription factor) or at the overt
phenotypic level (e.g., the variant is associated with, or known to cause, a
disease). Although many of the methods, analyses, and references we
comment on focus on single nucleotide variants (SNVs), quite a few of
these methods are applicable to other forms of variation as well. Table 1
provides a listing of example tools anddatabases that provide annotations
of the type we discuss. We consider the limitations of each of many
approaches and provide references to some of themore salient examples
of their use. We conclude with a few remarks on the future of genome
annotations and the use of such annotations in clinical and non-clinical
settings.
2. Types of annotation
2.1. Genomic position and functional elements
The simplest and most obvious form of sequence variant
annotation is determining the variant's position in the genome.
Position-based variant annotations are greatly facilitated by the
availability of reference genomes and web-based browsers that can
be used to graphically display genomic positions on those reference
genomes, such as the UCSC browser [13,14]. The position of a variant
Table 1
Example tools for human variant annotations.
Tool Website/reference Purpose/theme
UCSC genome browser http://www.genome.ucsc.edu/ Position-speciﬁc functional organization of the genome
dbSNP http://www.ncbi.nlm.nih.gov/projects/SNP/ Catalog variants with population-genetic annotations
OMIM http://www.ncbi.nlm.nih.gov/omim Catalog known disease-causing mutations
HapMap http://hapmap.ncbi.nlm.nih.gov/ Catalog variants with population-genetic annotations
COSMIC http://www.sanger.ac.uk/perl/genetics/CGP/cosmic Catalog of somatic mutations from tumor sequencing
TAMAL http://neoref.ils.unc.edu/tamal/ Provides functional and population-genetic annotations
Variant analyzer http://www.svaproject.org/ Provides functional annotations
PharmGKB http://www.pharmgkb.org/ Pharmacogenetics variant annotations
HGDP selection browser http://hgdp.uchicago.edu/cgi-bin/gbrowse/HGDP/ Browser for assessing signs of selection in the human genome
Association database www.genome.gov/gwastudies Results of genome wide association studies (GWAS)
SeattleSeq http://gvs.gs.washington.edu/SeattleSeqAnnotation/ Variant annotation
Gene ontology http://www.geneontology.org/ Biological, molecular and cellular annotations
KEGG pathways http://www.genome.jp/kegg/pathway.html Pathway analysis
DAVID http://david.abcc.ncifcrf.gov/ Multiple annotations
UniProt http://www.uniprot.org/ Protein elements
Transfac http://www.biobase-international.com Transcription factor databases
Genenetwork eQTL website www.genenetwork.org eQTL database
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genome, such as introns, exons, promoters, enhancers, silencers,
microRNA binding sites, conserved regions, etc. Annotating a variant
with respect to its position in functional genomic elements is crucial
for putting the likely functional effect of that speciﬁc variant into
perspective, as discussed in detail below [22]. The UCSC browser
provides information on functional genomic elements and their
positions in the genome as well as an easy way of representing the
position of an identiﬁed variant relative to a reference genome
[13,14].
There are few caveats with determining the position of a variant
in a genome either relative to other variants or with respect to
functional elements in a genome. First, not all functional elements in
the human genome have been identiﬁed, although their existence is
constantly being updated through functional studies. Second, humans
are a diploid species, so that each human contains two genomes: one
maternally-derived and one paternally-derived. The position of ge-
netic variants on a genome relative to other variants should thus be
determined with consideration of which chromosome or haplotype
they reside on. Characterizing haplotype or ‘phase’ information from
sequence data obtained from an individual is not trivial, but may be
important for putting the functional effects of those variants into
perspective [21,23]. Third, variant positions can also be determined
independently of a reference genome and therefore be assessed
merely relative to other variants in an individual genome via de novo
assemblies of individual genomes. However, such de novo assemblies
are notoriously difﬁcult for human genomes [15].
2.2. Population characteristics
The population characteristics of a variant are an important form
of initial annotation information. The frequency of a variant (or the
frequencies of alleles at a multiallelic locus) within different
populations is a useful indicator of the age of a variant. Frequency
information also provides insight into the population-speciﬁcity of the
variant – which could be a sign of selection effects ([24]; see below) –
or suggest that the variant, if it had never been observed before in
population studies, is a de novo mutation. However, the best way to
determine if a variant is de novo is to genotype the parents of the
carrier and determine if the variant was indeed inherited or not. Allele
frequency information has also been shown to be associated with
likely functional or phenotypic consequences of a variant [25–27].
Other population characteristics that are important for variant
annotation include linkage disequilibrium (LD) patterns exhibited by
the variant with other variants. Such patterns can provide information
about the haplotypic background upon which the variant arose andthe potential for use of other variants as surrogates or proxies for the
variant in question. Such information can greatly facilitate gene
mapping studies [28]. Population characteristic annotations of
variants are often recorded in databases such as the hapmap database
[7] and dbSNP [29].
2.3. Conservation
One of the most widely used methods for estimating the likely
functional impact of a variant is to investigate how conserved the
nucleotides are encompassing the variant (or amino acids if the
variant is in the coding region of a gene). If the wild-type or non-
variant nucleotides at the position are conserved across species, then
this could suggest that selection acted against alternative nucleotides
at that position on an evolutionary time scale, indicating not only the
likely functional or phenotypic signiﬁcance of those nucleotides but
also the deleterious nature of the variant nucleotides. Many programs
used to estimate the likely functional impact of a variant leverage
conservation information (e.g., [30]). However, conservation has been
shown to be only a reasonable surrogate, rather than a perfect
surrogate, for functionality and phenotypic relevance [31]. In addition,
lineage and species-speciﬁc functionality of nucleotides raises
questions about what species to include in an assessment of
conservation (see, e.g., [32]).
2.4. Biophysical modeling
One direct way to assess the likely functional impact of a DNA
sequence variant is to determine the inﬂuence of the nucleotide
substitution, indel, or larger structural anomaly on the structure of
DNA sequence encompassing that variant or a protein encoded by the
sequence harboring the variant. Although such biophysical modeling
has been pursued at the level of DNA to characterize and quantify the
structure and properties of unique sequences [33–35,31] it is far from
trivial to perform and its use to assess the effect of nucleotide
substitution requires extensive knowledge of not only the basic
properties of DNA, but how those basic features impact the
functioning of higher-order structures and processes such as proteins,
binding events, and interactions involving different DNA sequence-
mediated molecular structures.
Knowledge of protein structures associated with a gene whose
coding regions harbor variants is on much more solid footing, since
the characterization of the effects of particular residues or amino acids
on protein function is achievable with appropriate structural assays
and computational models [36,37]. However, not all proteins have
had their structures solved, nor do all amino acid substitutions result
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characterization. In addition, relatively few proteins have had both
mutant and wild-type structures solved, making it hard to evaluate
how well one can predict the inﬂuence of speciﬁc amino acid
substitutions on not only those proteins whose structures are solved,
but homologous (or paralogous) protein structures as well [38].
2.5. Prediction/classiﬁer analyses
In the absence of precise biophysical or functional models of DNA
sequence or protein structures, determining the likely effect of a
sequence variant on those structures can be pursued by building
predictive models based on various features associated with previously
characterized variants (e.g., sequence motifs, sequence conservation
levels, similarity to other variants, the results of biochemical assays
exploring those variants, etc.) that can discriminate known functional
from non-functional variants. The information about which features
appear to discriminate functional fromnon-functional variants can then
be applied to novel or previously uncharacterized variants in order to
estimate their likely functional potential. Prediction and classiﬁcation
analyses of this sort are used widely and form the basis of many
computer programs for evaluating the functional signiﬁcance of coding
variants [39,22,32,40–42], variants in regulatory genomic regions [43],
and somatic mutations in cancer [44,45]. Problems inherent in these
approaches are the need for specifying the variant ‘features’ that will be
used to create predictive models, since the chosen features might not
encompass the more important, yet unknown, features [40], and the
need for training data sets for the development of the predictor or
classiﬁer for which the absolute functionality of variants has been
determined.
2.6. Literature-based annotations of speciﬁc variants
The best way of assigning a functional annotation to an observed
sequence variant is to speciﬁcally study that variant using, e.g.,
relevant laboratory functional assays, transgenic mice, families with
clinical phenotypes possessing that variant, etc. The literature
contains thousands of papers describing the results of various assays
investigating the signiﬁcance of particular sequence variants. Acces-
sing this information to annotate an observed variant in an individual
genome is not entirely trivial as the reports in the literature describing
any variant will undoubtedly have nuances and caveats, and be very
context-speciﬁc. Databases such as OMIM [46] can clearly facilitate
searches for at least the overt phenotypic inﬂuence of a variant, as can
phenotype or disease-speciﬁc databases such as AlzGene [47].
Many reports describing the functional effects of human variants
leverage laboratory-based in vitro or model organism functional
assays, the generalizability or ultimate human in vivo signiﬁcance of
which is hard to gage. Recently, Ioannidis and Kavvoura [48] and
Cerulli and Goldstein [49] considered the results of in vitro studies
designed to assess the functional effects of speciﬁc naturally-
occurring human DNA sequence variants on the expression of genes
in cis and compared them to the results of association studies
involving those same variants with speciﬁc diseases. The authors
found only a weak correlation, suggesting that the results of contrived
laboratory-based functional assays probing the molecular effects of
variants do not necessarily predict which variants play a large role in
mediating disease susceptibility in the population at large. Despite
this, knowledge of the molecular effects of variants, in whatever
setting, can be important for making claims about the potential for
those variants to inﬂuence gross phenotypic expression as well as
those variants' potential for participating in pathogenetic processes
and networks that underlie diseases.
There is a growing trend to develop tools for mining the literature
on genetic variants by leveraging appropriate keywords, assay types,
etc. mentioned in published reports on the internet [50,51]. The basicidea is to bring together and synthesize information about genetic
variants and possibly make predictions about a novel variant based on
what is learned from the literature about related variants (see, e.g.,
[50,51]). However, there are clearly limits in the available published
knowledge that might create biases in developing such predictive
schemes [52].
2.7. Context-speciﬁc perturbation-based annotations
The functional effects of many sequence variants require appro-
priate environmental conditions to be present, and hence annotations
assigned to variants that exhibit an effect only in certain contexts are
important. For example, many variants have been found to exhibit
interactions with environments of one sort or another in the context
of disease susceptibility [53]. However, more speciﬁc interactions
involving drugs or chemicals have received a great deal of recent
attention and have led to databases cataloging evidence for such
interactions, such as the ToxPO database [54] and, importantly, the
Pharmacogenetics Knowledge Base or ‘PharmGKB’ [55]. Many studies
and databases providing context-speciﬁc functional annotations of
genetic variants are not necessarily population-based, but may
leverage speciﬁc laboratory or model-organism based functional
assays [56].
2.8. Molecular phenotype-based association study results
Many researchers have pursued tests of associations between
genetic variants and the expression levels of genes measured on a
genome-wide scale via microarray technologies [57,58]. Such studies
typically involve measuring gene expression levels from tissues
obtained on many individuals, genotyping those individuals, and
then testing the statistical association between the genotyped
variants and the expression levels of the genes. These studies have
revealed thousands of putative statistical associations between
genetic variations, working either in cis or in trans, and the expression
levels of many genes [59]. Association studies of this type have been
expanded to consider associations between genetic variants and
protein levels [60] as well as the methylation levels of different
genomic sites [61]. In fact, some investigators have considered
integrating information about genetic variants inﬂuencing both, e.g.,
expression and methylation levels of certain genes [62].
Annotating variants with respect to their statistical association
with changes in expression levels (expression Quantitative Trait Loci
or ‘eQTLs’), protein levels (‘pQTLs’), and methylation levels (‘mQTLs’)
can be very revealing about the likely functional effects of the variant,
especially since it has been shown that variants that inﬂuence
expression levels of genes from association studies are more likely
to be associated with overt phenotypes and/or disease [63]. Two
important issues in annotating variants in the context of their
inﬂuence on expression level, protein level, and methylation level
are that these phenomena are tissue-speciﬁc, making it important to
consider the tissue or cell type that the assays were performed with.
In addition, the statistical criteria for declaring a signiﬁcant associa-
tion between a variant and, e.g., the expression level of a genemust be
considered since genome-wide association studies with small sample
sizes – which is the rule for most eQTL, pQTL, and mQTL studies – can
result in many false positive and false negative associations.
2.9. Clinical phenotype-based association study results
By far the most important and relevant variant annotation
concerns knowledge of what overt, clinical phenotypes and diseases
a variant may either cause or be associated with. The assessment of
which overt or clinical phenotypes a variant might cause or be
associated with is in contrast to variants exhibiting associations with
molecular physiologic phenotypes such as gene expression or protein
Table 2
Studies investigating multilocus genetic models for predicting or classifying diabetics.
Reference #
Variants
Study design Outcome
Lyssenko et al.
(2005) [100]
6 Predictive Effect of multilocus genetic risk is
roughly equivalent to estimated
relative risk
Weedon et al.
(2006) [101]
3 Classiﬁcation Low predictive power for multilocus
genetic model only
Lango et al.
(2008) [102]
18 Classiﬁcation Adding genetic risk variants only
marginally increases discriminative
accuracy above BMI, age and sex
Lu and Elston
(2008) [103]
12 Classiﬁcation Addition of 9 variants and 4
environmental variables to model by
Weedon et al.[101] marginally
increases AUC estimates
Lyssenko et al.
(2008) [104]
16 Predictive Addition of genetics to clinical models
improves discriminatory power and
reclassiﬁcation of patients in a small
but statistically signiﬁcant way
Meigs et al.
(2008) [105]
18 Predictive Addition of genetics only slightly
increases risk prediction accuracy
above common clinical risk factors
alone
Cauchi et al.
(2008) [106]
22 Classiﬁcation 15-loci model sufﬁcient to attain high
discriminative accuracy within French
population
vanHoek et al.
(2008) [107]
18 Predictive Adding genetic risk variants only
marginally increases discriminative
accuracy above BMI, age and sex
Lu et al. (2009)
[108]
18 Classiﬁcation Addition of 15 genetic loci to model
from Lu and Elston [103] provided only
limited improvement in discriminative
accuracy
Miyake et al.
(2009) [109]
11 Classiﬁcation Adding genetic risk variants only
marginally increases discriminative
accuracy above BMI, age and sex
Talmud et al.
(2010) [110]
20 Predictive Addition of genetics to clinical models
only minimally improves predictive
accuracy and reclassiﬁcation
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phenotypes, since the molecular effects of a variant may be mitigated
or offset by the effects of other genes or environmental conditions,
such as pharmacotherapies, and hence not result in an overt
phenotype. Databases such as OMIM [64] catalog disease-associated
variants and are extremely useful for annotating previously observed
variants likely to be causally associated with rare Mendelian diseases.
In addition, the results of recent genome wide association studies
(GWAS) have provided over 1000 very compelling associations
between particular genetic variants, mostly SNVs, and common,
complex diseases and phenotypes of all sorts ([3] and http://www.
genome.gov/GWAstudies/).
Two important issues with the use of association study results like
those recorded in OMIM and GWAS results databases [65] for genome
annotation include the fact that they rely on previous knowledge of
the association and hence cannot be used for novel variants, and that
one must consider the statistical signiﬁcance of the association (as
with eQTL, pQTL, and mQTL analysis) [66].
2.10. Multilocus phenotypic predictions/disease risk assessment
Once associations between multiple variants and a phenotype
have been described, it is important to consider the collective effects
of these variants on phenotypic expression. This is not trivial since it
requires knowledge or assumptions about how the variants interact,
but is of great interest since such models could be used for predicting
or classifying individuals harboring speciﬁc variants into, e.g.,
diagnostic or prognostic categories with respect to disease. There
are twoways relevantmodeling and analyses can be pursued. The ﬁrst
is to directly assess the collective effects of variants in an appropriate
data set with individuals studied before and after the onset of the
phenotype so that predictions can be made. The second is to model
the impact of the collection of variants by making assumptions about,
e.g., their effect sizes, frequencies, combined inﬂuence (such as
additive or multiplicative effects), the incidence and prevalence of the
phenotype in question and how incidence and prevalence are
impacted by the collective inﬂuence of the variants, and the inﬂuence
of non-genetic factors. The second method is used routinely, as many
association studies and candidate gene analyses have been pursued in
isolation and not in one all-encompassing longitudinal study, creating
a need to synthesize the information across such studies. Obviously,
such studies are highly problematic since the assumptions they make
may not be correct [67].
Despite this fact, phenotype prediction from genetic (and non-
genetic) data is seen as the holy grail of genomic medicine and disease
prevention, even though there are great concerns about how such
information will be perceived and utilized [68]. Recent studies in
diabetes and cardiovascular disease suggest that the addition of
previously associated genetic risk loci in clinical risk models of those
diseases increases both discriminative and predictive accuracy, albeit
only marginally. Typically, the strongest predictors of disease onset
are known clinical risk factors such as body mass index, age, or
gender. While genetic risk variants can have unequivocal associations
with disease, the addition of multilocus genetic risk to clinical models
rarely provides large gains in predictive accuracy, and models built
solely on genetic factors tend to perform comparably to non-genetic
risk models. Table 2 provides a list of studies exploring multilocus risk
or classiﬁcation models for diabetes and a summary of the outcomes
of these studies.
Relevant analyses that lead to genomic variation annotations of
this sort are problematic for many reasons that go beyond mathe-
matical assumptions about how independently characterized multi-
ple variants might work together to inﬂuence phenotypic expression.
For example, most studies that have identiﬁed variants to be used in
a multilocus model exploit extant or prevalent cases and controls.
Hence the resulting models provide classiﬁcations of individualsbased on phenotype rather than true predictions of who will develop
a phenotype over time. In order to make true predictions one would
need either to pursue a longitudinal study with individuals without
the phenotype at the start or have very reliable incidence data, and
getting appropriate incidence data is not trivial [67]. Other issues
involve the need to accommodate environmental effects, interrela-
tionships with other diseases, and a need to recognize the limitations
of classiﬁcations and predictions based solely on what is likely to be
incomplete available knowledge of the genetic architecture of the
phenotypes in question [69,70].
2.11. Pathway-based annotations
Genes do not work in isolation to inﬂuence the expression of a
phenotype, but rather work collectively to inﬂuence a particular
biological process, biochemical pathway or metabolic network that
mediates that phenotype's expression. These processes and networks
are replete with feedback and compensatory mechanisms, making it
difﬁcult to predict the phenotypic impact of isolated genetic variants,
especially in the case of common chronic diseases. Similarly, gene
regulatory elements tend to contain redundant and/or tissue-speciﬁc
elements making it difﬁcult to interpret the ultimate phenotypic
impact of variants that disrupt, e.g. transcription factor binding sites.
Thus, one needs to consider the inﬂuence of a variant that has not
been characterized before in the context of the other genes and
genomic elements it interacts with [71–73].
Annotations that involve sets of variants, rather than an individual
variant, are limited by the available knowledge as to how genes and
genomic elements interact and mediate basic molecular processes.
Despite this fact, many attempts have been made to annotate the
Table 3
Recent individual whole genome sequencing studies with variant annotations.
Individual Reference Platform Annotations
JC Venter Venter (2007) [92]; Levy et
al. (2007) [15]
Sanger
sequencing
Disease, traits,
ancestry
S. Quake Ashley et al. (2010) [93] Helicos Disease, traits,
ancestry
Family with
Miller
syndrome
Roach et al. (2010) [95] Complete
Genomics, Inc.
Speciﬁc disease
mutations
J. Lupski Lupski et al. (2010) [94] SOLiD Speciﬁc disease
mutations
NA19240 Moore et al. (2011) [11] SOLiD Disease, traits,
ancestry
NA18507 Moore et al. (2011) [11] SOLiD; Illumina Disease, traits,
ancestry
Anonymous
Chinese Asian
Moore et al. (2011) [11] Illumina Disease, traits,
ancestry
Anonymous
Korean Asian
Moore et al. (2011) [11] Illumina Disease, traits,
ancestry
J. Watson Moore et al. (2011) [11] Roche 454 Disease, traits,
ancestry
NA07022 Moore et al. (2011) [11] Complete
genomics
Disease, traits,
ancestry
NA12878 Moore et al. (2011) [11] SOLiD Disease, traits,
ancestry
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that disrupt the function of relevant genes [74–78]. Conversely, the
phenotypic impact of variants can be predicted on the basis of the
biological processes the impacted genes participate in, allowing the
inference of gene-phenotype relationships without prior phenotypic
information. Moreover, methods such as co-expression or other
network inference techniques can be utilized to infer biological
process and the potential phenotypic impact of variants in genes of
unknown function [71–78]. Thus, pathway and network based
annotation approaches can be powerful approaches to inferring
phenotypic information where direct links to phenotype do not exist.
2.12. De novo association analyses involving multiple genomes
In the absence of prior information one might leverage to annotate
the likely effect of a variant, one could conduct a de novo study to
determine the phenotypic relevance of the variant. Such studies could
include eQTL mapping, in vitro laboratory or model organism-based
functional assays, association analyses, or any one of the study types
that reﬂect the annotation types discussed in this review. Of these, the
study types receiving the most attention are, as noted, association
studies involving medically-relevant phenotypes. Designing and
conducting such studies are not trivial as they are costly, laborious
and time-consuming, especially if they involve the notion that an
identiﬁed variant is one of many different rare variants that perturb a
genomic element in a similar way [5]. Association studies can bemade
more efﬁcient through the use of extant control data or pooling
strategies [79], although such strategies are not without their
problems.
The creation and use of genomic databases, such as dbGAP [80] or
other medical genomics databases [81], which harbor DNA sequence
variation information on individual genomes with some phenotypic
information available from the subjects whose genomes were
assayed, will facilitate the annotation of variations via de novo
association studies. In fact, it is not hard to imagine a timewhenwhole
genome sequencing (WGS) will become routine and databases
harboring the WGS information will be created, such that if a variant
or variant type is observed, phenotypic associations involving that
variant can be pursued in short order. Obviously, and justiﬁably,
informed consent, anonymity, liability, and other issues concerning
the use and distribution of individuals' genome information will loom
large in these contexts.
2.13. Ancestry
Variation in the frequency of a sequence variant across different
populations can point to the origins (or even signs of selection) of that
variant. With enough genetic markers across the genome that exhibit
frequency differences across populations (‘Ancestry Informative
Markers’) estimates of an individual's ancestry can be made [82].
These same principles can be applied to speciﬁc genomic regions
implicating a variant [83,84].
2.14. Within-species evidence for selection
Many approaches to assessing evidence that a genomic region
shows signs of selection – and hence is very likely to be functional or
phenotypically-relevant – leverage within-species, as opposed to
cross-species, information [24]. It is therefore possible to annotate
variants and genomics regions harboring variants on the basis of
evidence that they exhibit signs of selection. There are many different
methods for assessing signs selection, and these methods do not
always agree [24]. However, a recent paper describes an aggregate or
consensus method for assessing selection that shows promise in
differentiating variants that are truly reﬂective of selection vs. those
that are not [85]. In addition, Lohmuller et al. [86] have consideredhow admixed populations can be studied for evidence of selection in
particular genomic regions, thus providing an additional level of
annotation for variants identiﬁed in individuals with mixed ancestry.
2.15. Somatic cell and tumor genome annotations
There is growing interest in identifying somatic mutations that
contribute to cancer [87]. Annotating somatic mutations for their
properties involves determining if, in fact, a variant is somatically
acquired. This involves comparing an individual's tumor genomewith
his or her germline genomic DNA [88]. Databases that catalog somatic
mutations in cancer exist, such as the COSMIC database [89]. These
databases build off individual sequencing studies of tumors, such as
those recently pursued by Link et al. [90] which identiﬁed a number of
inherited and somatic mutations involved in a leukemia, and Ding et
al. [88] which identiﬁed somatic variants contributing to a metastastic
tumor which were veriﬁed in functional analyses of those variants via
xenograft models. Annotating novel somatic mutations for their likely
tumorigenic effect is not trivial but can be pursued through the
assessment of patterns among genes and pathways observed to be
mutated in large consortium studies of tumors such as The Cancer
Genome Atlas (TCGA) and the International Cancer Genome Consor-
tium [91].
3. Example studies leveraging annotation
There have been many very recent precedent-setting individual
whole genome variant annotation studies (Table 3). Most of these
studies have leveraged disease and trait association study-based
annotations along with an assessment of overall ancestry of the
individuals whose genome were sequenced. For example, J. Craig
Venter's genome and variations of relevance to many phenotypes are
discussed in his autobiography [92] as well as a paper describing the
diploid assembly of his genome [15]. The genome of scientist Steven
Quake was the subject of a recent report that estimated his lifetime
risk of many common polygenic diseases as a function of variants
identiﬁed in his genome that had been shown previously to be
associated with these diseases [93]. Similarly, a recent study of an
individual Charcot-Marie-Tooth neuropathy leveraged WGS to iden-
tify variants likely to contribute to that disease [94]. A similar study
usedWGS in a 4-member family and sophisticated variant annotation
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syndrome phenotype in the 2 offspring of the family [95].
Two additional studies have considered annotating the genomes of
multiple individuals. Moore et al. [11] considered disease association-
based annotation and ancestry of 10 recently published individual
genomes. Pelak et al. [4] explored the frequency and likely functional
impact of variants identiﬁed in 20 individual whole genomes and,
although they did not consider detailed annotations of each
individual, they did characterize the number of likely deleterious
and novel mutations per genome and found that, on average, each
human genome may carry as many as 144,000 unique variants.
The use of DNA sequencing and variant annotations in clinical
decision-making has also recently witnessed some sensational
successes. For example, in a 5 year old boy who had undergone
more than 100 surgical operations, was almost constantly hospital-
ized and intermittently septic, whole exome sequencing proved to be
life-saving. The idiopathic disease that this boy was suffering from
proved to be from a heretofore not seen mutation in the gene XIAP,
and led his team of physicians to have him undergo a bone marrow
transplant. This patient is now thriving and represents the ﬁrst case of
an idiopathic disease diagnosed and treatment-guided by sequencing
[96]. Similarly, there are examples in tumor sequencing studies in
which the causative mutation, as determined by sequencing and
contrasting of the tumor and germline genomes, led to appropriate
tailored therapy and an excellent therapeutic response [97,98]. In
aggregate, such cases are the ﬁrst to document the remarkable
potential of not only sequencing, but appropriate annotation of the
data, to improve the prognosis of individuals with serious medical
conditions.
4. Future directions for annotating individual genomes
It is quite clear that advances in DNA sequencing technology, as
well as assembly and variant calling algorithms, will lead to a situation
in which the generation of DNA sequence is not a major impediment
to identifying variants that may contribute to disease. Rather, future
genetics research will focus on interpreting and making sense of the
variations identiﬁed from the use of such sequencing technologies
[10,99], for example via the strategies outlined in this review.
However, annotating variants is an activity that also has some
inherent challenges. For example, humans are diploid, so that anno-
tating variants may require understanding the sequence context
within which variants reside. Thus, phase information from DNA
sequencing studies may be necessary for appropriate functional
annotations, but is not trivial to obtain currently [21,23]. Importantly,
any one of the annotation methods described here has limitations, as
we have tried tomake clear. In addition, depending on the application,
integrating different types of annotation make sense and the best way
to do this is an open question. For example, in clinical decisionmaking
settings involving novel variants, the knowledge that other variants
in a gene in question have been shown to inﬂuence disease, the
particular variant in question has been shown to likely damage the
gene or genomic element it resides in, and the variant has been shown
to be associated with the expression level of that gene in tissues of
relevance to the disease, would make the case for the role of that
variant in mediating a patient's disease easier to make than if only
evidence from a single annotation existed. Also, in the context of
tumor variant annotations, it makes sense to askwhat other variations
may exist in the tumor beyond the one of focus, how those variants
may impact gene function, and, further how the genes impacted by
those variants inﬂuence a fundamental process or pathway that
includes the gene with the primary variant of interest.
Facilitating the integration of variant annotations will thus be an
important future activity. The creation of databases, graphical
methods displaying integrated annotation results, and statistical
analysis and query tools will all help. In the context of disease riskpredictions, longitudinal and clinical studies exploring the role of
multiple variants must be pursued. Furthermore, the annotation
needs to be developed must be adapted for different uses. For
example, the interpretative depth and needs for the research
community are quite distinct from that of individual physicians or
patients. As more individuals access their whole genomic sequence to
determine their unique biologic features including disease suscepti-
bility, pharmacogenomic interactions, and ancestry, a different set of
annotation tools to represent this information will be required. For all
such applications it will be vital for the dissemination of the
information to be done in intuitively interpretable, reliable, and
ethically-aware ways.Acknowledgments
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